样式: 排序: IF: - GO 导出 标记为已读
-
CABINET presents cabozantinib as a new treatment option for NETs Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2024-09-24 David Killock
Patients with advanced-stage neuroendocrine tumours (NETs) have limited treatment options following disease progression after 1–2 lines of systemic therapy. Now, newly published data from the phase III CABINET trial, simultaneously presented at the ESMO Congress 2024, demonstrate the efficacy of cabozantinib in this setting. In CABINET, patients with locally advanced or metastatic well or moderately
-
Neoadjuvant immunotherapy for dMMR and pMMR colorectal cancers: therapeutic strategies and putative biomarkers of response Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2024-09-24 Christopher J. M. Williams, Allyson M. Peddle, Pashtoon M. Kasi, Jenny F. Seligmann, Campbell S. Roxburgh, Gary M. Middleton, Sabine Tejpar
-
A new standard of care for leiomyosarcoma Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2024-09-19 Peter Sidaway
Patients with advanced-stage leiomyosarcoma, a type of soft-tissue sarcoma that occurs predominantly in uterine locations, typically receive doxorubicin and have a median overall survival (OS) of ~20 months. Now, data from a randomized phase III trial demonstrate that adding trabectedin to doxorubicin significantly improves OS. A total of 150 patients with previously untreated locally advanced or metastatic
-
Dual HER2 inhibition: mechanisms of synergy, patient selection, and resistance Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2024-09-13 Adrienne G. Waks, Olga Martínez-Sáez, Paolo Tarantino, Fara Braso-Maristany, Tomás Pascual, Javier Cortés, Sara M. Tolaney, Aleix Prat
-
Vorasidenib: a new hope or a false promise for patients with low-grade glioma? Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2024-09-12 Stanislav Lazarev, Kunal K. Sindhu
Despite recent FDA approval, the clinical utility of vorasidenib in the treatment of IDH-mutant low-grade gliomas remains unclear. Herein, we critique the pivotal trial of vorasidenib, and highlight the questionable choice of control intervention and end points, ethical concerns, as well as the uncertain efficacy observed, and argue that the approval might be premature given the high cost of this drug
-
New clinical trials in CUP and a novel paradigm in cancer classification Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2024-09-11 Elie Rassy, Fabrice André
-
The age of foundation models Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2024-09-05 Jana Lipkova, Jakob Nikolas Kather
-
Immunotherapy for ovarian cancer: towards a tailored immunophenotype-based approach Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2024-09-04 Eleonora Ghisoni, Matteo Morotti, Apostolos Sarivalasis, Alizée J. Grimm, Lana Kandalaft, Denarda Dangaj Laniti, George Coukos
-
Redefining priorities: a call for patient-centred cancer care and research Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2024-08-29 Carolyn Taylor
My close experience with cancer and interactions with other patients, caregivers and health-care providers have shaped my belief that patients must be at the centre of research and care. In this Comment, I advocate for a redirection of research efforts in order to measure patient-centred outcomes and address health disparities.
-
Translating biological insights into improved management of endometrial cancer Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2024-08-28 Jeffrey A. How, Amir A. Jazaeri, Shannon N. Westin, Barrett C. Lawson, Ann H. Klopp, Pamela T. Soliman, Karen H. Lu
-
Tumour mutational burden: clinical utility, challenges and emerging improvements Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2024-08-27 Jan Budczies, Daniel Kazdal, Michael Menzel, Susanne Beck, Klaus Kluck, Christian Altbürger, Constantin Schwab, Michael Allgäuer, Aysel Ahadova, Matthias Kloor, Peter Schirmacher, Solange Peters, Alwin Krämer, Petros Christopoulos, Albrecht Stenzinger
-
Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2024-08-23 Maxwell R. Lloyd, Komal Jhaveri, Kevin Kalinsky, Aditya Bardia, Seth A. Wander
-
The MARIPOSA trials — implications for the treatment of EGFR-mutant NSCLC Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2024-08-19 Fatemeh Ardeshir-Larijani, Suresh S. Ramalingam
In the past 2 years, substantial improvements have been made in the management of advanced-stage EGFR-mutant non-small-cell lung cancer. Recent studies have suggested added benefit from the combination of third-generation tyrosine-kinase inhibitors with either chemotherapy or a bispecific antibody targeting EGFR and MET. Herein, we summarize these advances and their implications for clinical practice
-
Applications of cell therapy in the treatment of virus-associated cancers Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2024-08-19 Keri Toner, Chase D. McCann, Catherine M. Bollard
-
Blinatumomab improves outcomes in adult MRD-negative BCP-ALL Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2024-08-12 Diana Romero
Adults with B cell-precursor acute lymphoblastic leukaemia (BCP-ALL) negative for minimal residual disease (MRD) after induction chemotherapy have a superior prognosis relative to those with MRD+ status, although many will eventually have disease relapse. Now, data from the phase III E1910 trial demonstrate that addition of the CD19 × CD3 bispecific T cell engager blinatumomab to consolidation chemotherapy
-
Author Correction: Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2024-08-02 Antonio Marra, Sarat Chandarlapaty, Shanu Modi
Correction to: Nature Reviews Clinical Oncology https://doi.org/10.1038/s41571-023-00849-9, published online 8 January 2024.
-
Anlotinib plus benmelstobart and chemotherapy are effective in ES-SCLC Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2024-07-29 Diana Romero
Patients with extensive-stage small-cell lung cancer (ES-SCLC) usually receive platinum-based chemotherapy plus an immune-checkpoint inhibitor (ICI) as first-line therapy, although disease relapse is a concern. Now, data from the phase III ETER701 trial demonstrate that the combination of the anti-angiogenic agent anlotinib plus the anti-PD-L1 antibody benmelstobart and chemotherapy has promising efficacy
-
Spatial landscapes of cancers: insights and opportunities Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2024-07-23 Julia Chen, Ludvig Larsson, Alexander Swarbrick, Joakim Lundeberg
-
BrECADD raises the bar in classical Hodgkin lymphoma Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2024-07-22 David Killock
The eBEACOPP regimen, consisting of bleomycin, vincristine, procarbazine and prednisone plus escalated doses of etoposide, doxorubicin and cyclophosphamide, is a standard frontline treatment for classical Hodgkin lymphoma (cHL). This intensive regimen confers the highest primary cure rates but also considerable and often persistent treatment-related morbidities. Now, data from the HD21 trial demonstrate
-
Tisotumab vedotin effective in recurrent cervical cancer Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2024-07-22 Peter Sidaway
Patients with recurrent advanced-stage and/or metastatic cervical cancer typically have a poor prognosis with limited treatment options available. Now, data from the phase III innovaTV 301 trial demonstrate the efficacy of the tissue factor-targeted antibody–drug conjugate tisotumab vedotin in this setting. A total of 502 patients with advanced-stage and/or metastatic cervical cancer who previously
-
HER2-targeted therapies beyond breast cancer — an update Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2024-07-22 Jeesun Yoon, Do-Youn Oh
-
BCMA-directed therapy for early relapsed and/or refractory multiple myeloma Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2024-07-19 Niels W. C. J. van de Donk, Sonja Zweegman
-
Targeting chromosomal instability in patients with cancer Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2024-07-11 Duaa H. Al-Rawi, Emanuele Lettera, Jun Li, Melody DiBona, Samuel F. Bakhoum
-
Is NETTER-2 a practice-changing trial? Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2024-07-09 Jonathan Strosberg, Mauro Cives
The NETTER-2 trial provides the first phase III evidence that 177Lu-dotatate is active as first-line therapy in patients with gastroenteropancreatic neuroendocrine tumours with a Ki-67 proliferative index of 10–55%. This approach is an important addition to the first-line therapeutic armamentarium, although treatment selection based on patient-specific and tumour-specific characteristics remains appropriate
-
Emerging advances in defining the molecular and therapeutic landscape of small-cell lung cancer Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2024-07-04 Triparna Sen, Nobuyuki Takahashi, Subhamoy Chakraborty, Naoko Takebe, Amin H. Nassar, Nagla A. Karim, Sonam Puri, Abdul Rafeh Naqash
-
Just scratching the surface: novel treatment approaches for multiple myeloma targeting cell membrane proteins Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2024-07-03 Paola Neri, Noémie Leblay, Holly Lee, Annamaria Gulla, Nizar J. Bahlis, Kenneth C. Anderson
-
Asciminib is safe and effective in patients with newly diagnosed CML Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2024-06-25 Diana Romero
Four BCR–ABL1 tyrosine-kinase inhibitors (TKIs) are approved for patients with newly diagnosed chronic myeloid leukaemia (CML): the first-generation agent imatinib and three second-generation TKIs, which have greater efficacy but also higher toxicity relative to imatinib. Now, results from the phase III ASC4FIRST trial reveal favourable outcomes in this setting with asciminib, an allosteric BCR–ABL1
-
Vimseltinib improves outcomes in tenosynovial giant cell tumour Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2024-06-24 David Killock
Tenosynovial giant cell tumour (TGCT) is a locally aggressive neoplasm of the tendons and cannot always be managed surgically. TGCT is driven by dysregulated CSF1 production and CSF1R-dependent inflammatory macrophages, and the CSF1R-directed multitargeted tyrosine-kinase inhibitor (TKI) pexidartinib is an FDA-approved systemic treatment for this disease but can cause potentially fatal cholestatic
-
NICHE-2 validates the efficacy of neoadjuvant ICIs in dMMR colon cancer Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2024-06-21 David Killock
Immune-checkpoint inhibitors (ICIs) have revolutionized the treatment of advanced-stage DNA mismatch repair-deficient (dMMR) colorectal cancers. The NICHE trial revealed the promise of ICIs as neoadjuvant therapy for patients with locally advanced dMMR colon cancer, and new data from the phase II NICHE-2 trial confirm the safety and efficacy of this strategy. NICHE-2 involved 115 patients with locally
-
Promising outcomes with liso-cel in patients with R/R follicular lymphoma Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2024-06-21 Diana Romero
Patients with follicular lymphoma (FL) generally have favourable outcomes after receiving first-line immunochemotherapy; however, treatment options are limited for those with relapsed and/or refractory (R/R) disease, especially if they have high-risk disease. Now, data from the phase II TRANSCEND FL trial demonstrate the efficacy of the CD19-targeted chimeric antigen receptor (CAR) T cell product lisocabtagene
-
Isatuximab–VRd quadruplet shows promise in transplant-ineligible NDMM Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2024-06-18 David Killock
Quadruplet regimens comprising an anti-CD38 antibody, proteasome inhibitor, immunomodulatory agent and a glucocorticoid have become the standard of care for transplant-eligible patients with newly diagnosed multiple myeloma (NDMM). A quadruplet regimen has also been approved for transplant-ineligible patients, although one built on a triplet containing melphalan instead of an immunomodulatory agent
-
Addition of sintilimab to standard therapy improves event-free survival Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2024-06-17 Peter Sidaway
Patients with locoregionally advanced nasopharyngeal carcinoma (NPC) typically receive induction chemotherapy followed by concurrent chemoradiotherapy. Nonetheless, 20–30% of patients will have disease progression on this regimen and, given the high level of PD-L1-positivity typically seen in this cancer type, an important question exists regarding the possibility of benefit from anti-PD-1 or anti-PD-L1
-
Osimertinib efficacious as maintenance therapy in patients with stage III NSCLC Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2024-06-17 Peter Sidaway
Patients diagnosed with unresectable stage III non-small-cell lung cancer (NSCLC) typically receive concurrent chemoradiotherapy (CRT) followed by consolidation therapy with the anti-PD-L1 antibody durvalumab. Nonetheless, data from several studies suggest that patients with driver mutation-positive tumours often derive limited benefit from this approach. Now, data from the phase III LAURA trial demonstrate
-
Neoadjuvant ipilimumab–nivolumab superior to adjuvant nivolumab Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2024-06-14 Peter Sidaway
Data from phase II trials indicate that patients with resectable melanoma are likely to derive benefit from neoadjuvant immune-checkpoint inhibitors (ICIs), and that those with a major pathological response (MPR, defined as ≤10% residual viable tumour material) are unlikely to require subsequent therapy. Now, data from the phase III NADINA trial confirm these findings, as well as the superiority of
-
Towards equitable AI in oncology Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2024-06-07 Vidya Sankar Viswanathan, Vani Parmar, Anant Madabhushi
-
Exploiting bacteria for cancer immunotherapy Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2024-06-05 Seong-Young Kwon, Hien Thi-Thu Ngo, Jinbae Son, Yeongjin Hong, Jung-Joon Min
-
Bispecific and multispecific antibodies in oncology: opportunities and challenges Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2024-05-31 Maria-Elisabeth Goebeler, Gernot Stuhler, Ralf Bargou
-
RADICALS-HD sheds light on the role of ADT addition to post-operative radiotherapy Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2024-05-30 Diana Romero
The addition of short-course androgen-deprivation therapy (ADT) to upfront radiotherapy is the standard-of-care approach for patients with intermediate-risk or high-risk localized prostate cancer; however, the role of ADT in those receiving radiotherapy after radical prostatectomy is unclear. Now, results from the phase III RADICALS-HD trial provide insights that could help to guide treatment decision
-
Ponatinib superior to imatinib in Ph+ ALL Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2024-05-28 Peter Sidaway
BCR–ABL1 tyrosine kinase inhibitors, in combination with chemotherapy and/or steroids, are the standard-of-care therapy for patients with newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukaemia (ALL). Nonetheless, whether these agents are equally effective has remained unclear. Now data from the phase III PhALLCON trial demonstrate that the third-generation inhibitor ponatinib
-
Adding ibrutinib to frontline therapy improves outcomes in transplant-eligible patients with MCL Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2024-05-24 David Killock
For eligible patients with mantle cell lymphoma (MCL), consolidative autologous haematopoietic stem cell transplantation (ASCT) is a standard component of frontline therapy but is not universally used owing to resource constraints and tolerability concerns, as well as unclear benefit with improved induction, maintenance and salvage therapies. Now, data from the phase III TRIANGLE trial demonstrate
-
Gaining ground in personalized breast cancer therapy: lesson learned from PHERGain Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2024-05-22 Maria Vittoria Dieci, Valentina Guarneri
De-escalation of treatment for HER2+ breast cancer is a priority, given the increase in cure rates owing in part to improved HER2-targeted therapies. In this regard, the neoadjuvant approach provides the ideal platform to test less-intensive treatment regimens. Here we highlight a study that demonstrated the role of the metabolic response after dual HER2 blockade as a method of selecting patients who
-
Predicting tumour origin with cytology-based deep learning: hype or hope? Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2024-05-21 Elie Rassy, Nicholas Pavlidis
The majority of patients with cancers of unknown primary have unfavourable outcomes when they receive empirical chemotherapy. The shift towards using precision medicine-based treatment strategies involves two options: tissue-agnostic or site-specific approaches. Here, we reflect on how cytology-based deep learning tools can be leveraged in these approaches.
-
Current understanding and management of CAR T cell-associated toxicities Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2024-05-20 Jennifer N. Brudno, James N. Kochenderfer
-
Cancer mRNA vaccines: clinical advances and future opportunities Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2024-05-17 Elias J. Sayour, David Boczkowski, Duane A. Mitchell, Smita K. Nair
-
Epidemiology of HPV-associated cancers past, present and future: towards prevention and elimination Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2024-05-17 Talía Malagón, Eduardo L. Franco, Romina Tejada, Salvatore Vaccarella
-
CAR T cells in multiple myeloma: lessons learned Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2024-05-07 Vinay Prasad
The question of whether chimeric antigen receptor (CAR) T cell therapies should be used in earlier lines (after 1–2 prior lines of therapy) in patients with relapsed and/or refractory multiple myeloma remains unanswered. Herein, I argue that the use of surrogate end points that lack a robust correlation with overall survival, as well as suboptimal control arms and use of post-progression therapies
-
NIR-II light in clinical oncology: opportunities and challenges Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2024-05-01 Zeyu Zhang, Yang Du, Xiaojing Shi, Kun Wang, Qiaojun Qu, Qian Liang, Xiaopeng Ma, Kunshan He, Chongwei Chi, Jianqiang Tang, Bo Liu, Jiafu Ji, Jun Wang, Jiahong Dong, Zhenhua Hu, Jie Tian
-
Laparoscopic hemihepatectomy is safe and effective Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2024-04-29 Peter Sidaway
Liver resection is an essential component of the management of patients with various primary or metastatic liver cancers, and many of these procedures can now be conducted laparoscopically. Nonetheless, whether hemihepatectomy (the resection of either the entire right or left side of the liver) can also be conducted laparoscopically without compromising oncological outcomes remains to be determined
-
Adjuvant pembrolizumab improves overall survival in patients with RCC Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2024-04-29 Peter Sidaway
Adjuvant therapy with the anti-PD-1 antibody pembrolizumab has been shown to significantly improve disease-free survival (DFS) relative to placebo in patients with resected nonmetastatic intermediate-to-high-risk renal cell carcinoma (RCC) in the phase III KEYNOTE-564 trial. Now, an update from this trial confirms that pembrolizumab also improves overall survival (OS). A total of 994 patients were
-
Adjuvant alectinib improves outcomes in ALK-mutant NSCLC Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2024-04-25 Diana Romero
Patients with resected ALK-positive non-small-cell lung cancer (NSCLC) requiring adjuvant therapy typically receive platinum-based chemotherapy, which is associated with limited clinical benefit and considerable toxicity. Now, data from the phase III ALINA trial demonstrate the efficacy of the ALK inhibitor alectinib in this setting. A total of 257 patients with resected stage IB–IIIA ALK-positive
-
From AACR 2024 Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2024-04-25 Diana Romero
The American Association for Cancer Research (AACR) Annual Meeting 2024 brought together ~22,000 delegates, either in San Diego or virtually. As the programme committee chairs explained in the opening plenary session, one of the main objectives of this meeting was to highlight how technological advances from the past decade are being integrated into patient care. Promising results were presented in
-
NALIRIFOX for metastatic pancreatic adenocarcinoma: hope or hype? Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2024-04-25 Christopher Nevala-Plagemann, Ignacio Garrido-Laguna
The FDA has approved nanoliposomal irinotecan, 5-fluorouracil, leucovorin and oxaliplatin (NALIRIFOX) for patients with metastatic pancreatic adenocarcinoma on the basis of results from the NAPOLI 3 trial, in which this four-drug regimen improved overall survival relative to a doublet regimen. Here we discuss how, in the context of prior results from the PRODIGE 4 trial testing 5-fluorouracil, leucovorin
-
Overtreatment of multiple myeloma and its precursor states: de-escalation is an urgent need in clinical practice and trials Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2024-04-22 Ghulam Rehman Mohyuddin, Aaron M. Goodman
Certain subsets of patients with multiple myeloma or its precursor conditions are overtreated with current approaches to therapy. Herein, we highlight several key areas where we believe de-escalation of treatment is needed. Dedicated trials to assess these de-escalation approaches and urgent changes to current clinical practices are needed.
-
Multiparametric MRI for characterization of the tumour microenvironment Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2024-04-19 Emily Hoffmann, Max Masthoff, Wolfgang G. Kunz, Max Seidensticker, Stefanie Bobe, Mirjam Gerwing, Wolfgang E. Berdel, Christoph Schliemann, Cornelius Faber, Moritz Wildgruber
-
ALND can be safely omitted for patients with sentinel-node macrometastases Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2024-04-18 David Killock
Omission of completion axillary lymph-node dissection (ALND) has been shown to mitigate lymphoedema without compromising survival outcomes in patients with clinically node-negative (cN0) breast cancer who have nodal metastasis detected upon sentinel lymph-node biopsy (SLNB), albeit in trials with limited statistical power and clinical representativeness. Now, data from the phase III SENOMAC trial in
-
Afami-cel provides a novel treatment option for rare sarcoma subtypes Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2024-04-18 Peter Sidaway
Patients with metastatic or unresectable synovial sarcoma or myxoid round cell liposarcoma (comprising 5–10% of all soft-tissue sarcomas) typically have limited long-term survival, especially after disease recurrence on first-line therapy. Now, data from the phase II SPEARHEAD-1 trial testing afamitresgene autoleucel (afami-cel), a CD4+ and CD8+ T cell product transduced with an affinity-enhanced MAGE-A4-specific
-
Lighting the torch: intratumoural T cell-to-stroma enrichment score as a predictor of immunotherapy response in urothelial carcinoma Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2024-04-15 David H. Aggen, Jonathan E. Rosenberg
-
Antiangiogenic–immune-checkpoint inhibitor combinations: lessons from phase III clinical trials Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2024-04-10 Hung-Yang Kuo, Kabir A. Khan, Robert S. Kerbel
-
Nucleic acid-based drugs for patients with solid tumours Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2024-04-08 Sebastian G. Huayamares, David Loughrey, Hyejin Kim, James E. Dahlman, Eric J. Sorscher
-
Pembrolizumab plus chemoradiotherapy effective in locally advanced cervical cancer Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2024-04-02 Peter Sidaway
Patients with locally advanced cervical cancer usually receive chemoradiotherapy (CRT) as first-line therapy, although this approach is generally not curative. Now, data from the phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 trial demonstrate that adding the anti-PD-1 antibody pembrolizumab to CRT reduces the risk of disease progression in this setting. A total of 1,060 women with node-positive FIGO stage